Choi SH, et al. - In triple-negative breast cancers (TNBC), researchers analyzed the clinical ability of programmed death ligand-1 (PD-L1) and other available factors in anticipating the clinical result. Out of 539 patients with newly diagnosed TNBC between 2004 and 2011, 117 patients were analyzed who had both tumor samples which PD-L1 protein expression could be assessed utilizing immunohistochemistry and initial staging ¹⁸F-fluorodeoxyglucose (FDG) positron emission tomography (PET) data to find available immunologic or metabolic factors. Findings suggested that PD-L1 and tumor metabolism may be able to anticipate an increase in treatment failures. Particularly, strong PD-L1 expression status was associated with distant metastasis-dominant recurrence pattern that requires intensive systemic therapy. Even after adjusting potential risk factors, the association between PD-L1 expression and survival outcomes maintained its significance.